Drug paraphernalia and controlled paraphernalia; drug checking products.
Summary
SB924 amends Virginia’s definitions of “drug paraphernalia” and “controlled paraphernalia” to carve out an explicit exception for “drug checking products” used to determine whether a controlled substance contains fentanyl contamination or a fentanyl analog that could cause physical harm or death. Under the bill, testing equipment is generally still covered by the paraphernalia definition, but narcotic testing drug checking products used for fentanyl detection are excluded from that category. The bill also makes a parallel change in the controlled paraphernalia statute so that these fentanyl-testing products are not treated as controlled paraphernalia.
The measure is aimed at allowing possession and use of fentanyl test strips and similar drug checking tools without exposing users or distributors to paraphernalia penalties. It preserves the existing prohibitions on drug paraphernalia and controlled paraphernalia for other items associated with illegal drug use, manufacture, packaging, or injection, while leaving in place the listed exceptions for legitimate medical, veterinary, naloxone, and harm reduction activities. The bill therefore narrows the reach of two criminal statutes without broadly changing Virginia’s drug enforcement framework.
Impact
SB924 amends Code of Virginia §§ 18.2-265.1 and 54.1-3466, creating a statutory exemption for fentanyl drug checking products from the definitions and penalties tied to drug paraphernalia and controlled paraphernalia. As a result, these products are no longer treated as contraband under those provisions when used to detect fentanyl contamination or fentanyl analogs. The change affects law enforcement, prosecutors, harm reduction programs, public health providers, and individuals who possess or distribute fentanyl testing tools, while leaving the rest of the paraphernalia regime intact.
Sentiment
The bill appears to have received broad support and little visible opposition. It advanced through the Senate and House with overwhelmingly favorable votes, including unanimous committee reporting and a 97-0 House passage, with only one dissenting vote on final Senate passage. The vote pattern suggests general agreement that the measure serves a public health purpose and should be narrowly tailored.
Contention
The main policy issue is the balance between drug enforcement and harm reduction. Supporters appear to favor exempting fentanyl test strips and similar products so they can be used to reduce overdose risk, while any potential concern would be that such tools could be viewed as facilitating illegal drug use or complicating enforcement of paraphernalia laws. The bill resolves that tension by limiting the exception to narcotic testing drug checking products for fentanyl detection and by leaving the broader prohibitions and other exceptions unchanged.